Iqvia Holdings Inc (NYSE:IQV) Shares Sold by Wealthfront Advisers LLC

Wealthfront Advisers LLC trimmed its position in shares of Iqvia Holdings Inc (NYSE:IQV) by 2.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,142 shares of the medical research company’s stock after selling 106 shares during the quarter. Wealthfront Advisers LLC’s holdings in Iqvia were worth $768,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. CWM LLC increased its stake in shares of Iqvia by 63.4% during the second quarter. CWM LLC now owns 165 shares of the medical research company’s stock worth $27,000 after acquiring an additional 64 shares during the period. Capital Investment Advisory Services LLC increased its stake in shares of Iqvia by 46.0% during the second quarter. Capital Investment Advisory Services LLC now owns 219 shares of the medical research company’s stock worth $34,000 after acquiring an additional 69 shares during the period. Massmutual Trust Co. FSB ADV acquired a new position in shares of Iqvia during the second quarter worth about $35,000. North Star Investment Management Corp. acquired a new position in Iqvia during the third quarter worth about $59,000. Finally, Cornerstone Advisors Inc. grew its position in Iqvia by 47.2% during the second quarter. Cornerstone Advisors Inc. now owns 399 shares of the medical research company’s stock worth $64,000 after buying an additional 128 shares during the period. Institutional investors and hedge funds own 89.80% of the company’s stock.

In related news, insider Kevin C. Knightly sold 4,278 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $158.50, for a total transaction of $678,063.00. Following the transaction, the insider now owns 4,084 shares of the company’s stock, valued at $647,314. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Group Holdings (Sbs) Advis Tpg sold 2,616,028 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $156.85, for a total transaction of $410,323,991.80. The disclosure for this sale can be found here. Insiders sold 2,627,251 shares of company stock worth $412,103,046 in the last ninety days. Insiders own 6.00% of the company’s stock.

Shares of NYSE IQV traded up $0.14 on Friday, hitting $143.49. The company’s stock had a trading volume of 1,381,317 shares, compared to its average volume of 1,447,123. Iqvia Holdings Inc has a 12-month low of $104.90 and a 12-month high of $164.13. The company has a market capitalization of $28.08 billion, a price-to-earnings ratio of 28.03, a price-to-earnings-growth ratio of 1.59 and a beta of 0.89. The company has a debt-to-equity ratio of 1.72, a current ratio of 1.14 and a quick ratio of 1.14. The stock has a 50 day moving average of $150.49 and a 200-day moving average of $147.91.

Iqvia (NYSE:IQV) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.38 by $0.01. Iqvia had a net margin of 2.31% and a return on equity of 15.95%. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.70 billion. During the same quarter in the prior year, the firm earned $1.29 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. Sell-side analysts expect that Iqvia Holdings Inc will post 5.88 EPS for the current fiscal year.

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of Iqvia from $160.00 to $180.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. Mizuho upgraded shares of Iqvia from a “neutral” rating to a “buy” rating and upped their target price for the stock from $150.00 to $175.00 in a research report on Friday, June 21st. Wells Fargo & Co upped their target price on shares of Iqvia from $170.00 to $178.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. SunTrust Banks upped their target price on shares of Iqvia from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Finally, Barclays set a $180.00 target price on shares of Iqvia and gave the stock a “buy” rating in a research report on Monday, July 15th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $163.09.

Iqvia Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also: How to interpret a stock’s beta number

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.